The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China
PDF | HTML | How to cite
Metrics: PDF 1190 views | HTML 1989 views | ?
Puyuan Xing1,*, Yixiang Zhu1,*, Ling Shan2, Sipeng Chen3, Xuezhi Hao1 and Junling Li1
1National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
3School of Public Health, Capital Medical University, Beijing, China
*These authors contributed equally to this work and should be considered co-first authors
Junling Li, email: [email protected]
Keywords: advanced non-small cell lung cancer (NSCLC), multiple treatments, taxane, nanoparticle albumin bound paclitaxel (Nab-PTX), secreted protein acidic and rich in cysteine (SPARC)
Received: June 06, 2017 Accepted: August 28, 2017 Published: September 20, 2017
For patients with pretreated advanced non-small cell lung cancer (NSCLC), more effective treatments are unmet. We conducted a study to explore the optimal treatment schedule of nanoparticle albumin bound paclitaxel (Nab-PTX) as a second line or later treatment for advanced NSCLC patients in China. Ninety-eight patients, who had experienced failure of prior treatment and received Nab-PTX monotherapy (130 mg/m2) on days 1, 8 of a 21-day cycle were included. The median progression-free survival (PFS) and overall survival (OS) were 4.34 months (95% confidence interval [CI] 3.508 to 5.165 months) and 11.73 months (95% CI 9.211 to 14.247 months), respectively. The objective responses rate (ORR) and disease control rate (DCR) were 22.4% and 74.5%. Prior treatment with taxane and line of therapy did not influence the efficacy of Nab-PTX. The main grade 3 to 4 toxicities were neutropenia (25.5%) and leukopenia (12.4%). Furthermore, 24 cases offered samples to assess secreted protein acidic and rich in cysteine (SPARC) expression. No statistical difference was observed in treatment efficacy between SPARC expression-negative and positive. The findings suggest that weekly Nab-PTX monotherapy is effective and well tolerated for patients with pretreated advanced NSCLC, regardless of prior taxane exposure or line of therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.